Phenotype and biochemical heterogeneity in late onset Fabry disease defined by <i>N215S</i> mutation - Fig 6

<p>Correlation analyses: Life time exposure to Lyso-Gb3 ([Lyso-Gb3]*age) and: clinical severity, (MSSI) for: (A) <i>N215S</i> males (n = 13), (B) <i>non-N215S</i> males (n = 9), (C) <i>N215S</i> females (n = 26), and (D) <i>non-N215S</i> females (n = 36); baseline GFR for: (E) <i>N215S</i> males (n = 13), (F) <i>non-N215S</i> males (n = 9), (G) <i>N215S</i> females (n = 26), and (H) <i>non-N215S</i> females (n = 33); LVMI for: (I) <i>N215S</i> males (n = 12), (J) <i>non-N215S</i> males (n = 9), (K) <i>N215S</i> females (n = 23), and (L) <i>non-N215S</i> females (n = 34); ns = not significant.